Evidence map›Paper›PMID 25858645›Full record

Trial reportBritish journal of haematology2015

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L Perkins, J Kimble Frazer, Warren Sanger, James R Anderson, Thomas G Gross and 5 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 2 countries.

Bruce ShiramizuDivision of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA.
Stanton GoldmanDivision of Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX, USA.
Lynette SmithDepartment of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA.
Melissa Agsalda-GarciaDivision of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA.
Paul GalardyDivision of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MD, USA.
Sherrie L PerkinsDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
J Kimble FrazerSection of Pediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Warren SangerDepartment of Cytogenetics, University of Nebraska Medical Center, Omaha, NE, USA.
James R AndersonDepartment of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA.
Thomas G GrossCenter for Global Health, NCI, NIH, DHHS, Rockville, MD, USA.
Howard WeinsteinDivision of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lauren HarrisonDepartment of Pediatrics, New York Medical College, Valhalla, NY, USA.
Matthew J BarthDepartment of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lara MussolinIstituto di Ricerca Pediatrico-Fondazione Città della Speranza-University of Padua, Padua, Italy.
Mitchell S CairoDepartment of Pediatrics, New York Medical College, Valhalla, NY, USA.
New York Medical College · USUniversity of Hawaii System · USUniversity of Nebraska at Omaha · USCenter for Global Health · USCittà della Speranza Foundation · ITMassachusetts General Hospital · USMayo Clinic · USMedical City Children's Hospital · USRoswell Park Comprehensive Cancer Center · USUniversity of Nebraska Medical Center · USUniversity of Oklahoma Health Sciences Center · USUniversity of Utah · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI MOKUAU, NOREEN, SHIRAMIZU, BRUCE T · 2012 to 2018
$21.1M
NCI NIH HHS CA98413-09NCI NIH HHS CA98543-09NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NIMHD NIH HHS U54 MD007584NIMHD NIH HHS U54MD007584
6 · The paper itself

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

Indexed as

Consolidation ChemotherapyAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBurkitt LymphomaCentral Nervous System NeoplasmsChildChild, PreschoolFemaleHumansMaleNeoplasm, ResidualPilot ProjectsReal-Time Polymerase Chain Reactioncentral nervous systemchildrenleukaemia

Identifiers

PMID25858645
PMCPMC4503484
OpenAlexW2067221216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.